Johnson Matthey wins new supply deal with US rare disease specialist
Johnson Matthey, the Cambridge UK global leader in science that enables a cleaner and healthier world, has struck a new five-year collaborative deal with genetics innovator Sarepta Therapeutics, Inc in the US.
The agreement means JM will continue supplying regulatory starting materials to support Sarepta’s major programmes used to treat Duchenne Muscular Dystrophy.
Sarepta markets itself as the leader in precision genetic medicine for rare diseases and is working to change the lives of people living with them.
Johnson Matthey’s Innovator Products & Solutions business that provides Custom Development and Manufacturing Services (CDMO) will produce these synthetic regulatory starting materials at their facilities in West Deptford, NJ and Devens, MA using their commercial-scale production trains.
“JM is delighted to further strengthen our relationship with Sarepta through this manufacturing agreement,” said Alex Zahiri, vice-president, Innovator Products & Solutions (CDMO) business at Johnson Matthey.
“Our collaboration with Sarepta signifies our continued commitment to existing and future PPMO and PMO programs, and Sarepta’s mission of engineering precision medicine for rare, devastating diseases.”
Bill Ciambrone, executive VP for Technical Operations at Sarepta, added: “Sarepta’s growing pipeline requires best in class manufacturing expertise in order to deliver on our commitment to patients.
“We are excited to expand and extend our agreement with Johnson Matthey as a manufacturing partner for our PMO and PPMO platforms.”
As leader in the complex technologies behind a wide variety of healthcare products and services, Johnson Matthey provides global customers with expertise in complex active pharmaceutical ingredient development and manufacture, solid form sciences, particle engineering, and catalysts.